If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carolyn Ho, MD: ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

Treatment with aficamten significantly improved exercise capacity compared with placebo. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for aficamten for ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...

Mavacamten treatment in oHCM patients led to new atrial fibrillation/flutter and heart failure, with frequent acute care episodes within months. Nearly half of the patients required dose adjustments, ...

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up (Family Features) You may find it difficult to wrap your mind ...

China NMPA approves Sanofi’s Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome: Paris Saturday, January 17, 2026, 11:00 Hrs ...